This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
by Zacks Equity Research
Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.
DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley
Omnicell (OMCL) Q3 Earnings Top, Pre-COVID-19 View Reinstated
by Zacks Equity Research
Omnicell's (OMCL) Service and other revenues improve in Q3 despite the pandemic-led business challenges.
Integra (IART) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q3.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
ABIOMED's (ABMD) international Impella revenues improved in Q2.
CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3
Cerner (CERN) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) third-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in margins.
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up
by Zacks Equity Research
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Boston Scientific (BSX) Q3 Earnings Top, Margins Decline
by Zacks Equity Research
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Top Analyst Reports for Thermo Fisher, SAP & Bristol-Myers
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific (TMO), SAP SE (SAP) and Bristol-Myers Squibb (BMY).
LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service
by Zacks Equity Research
Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.
Stock Market News for Oct 22, 2020
by Zacks Equity Research
Benchmarks closed slightly lower on Wednesday as investors continued to look for signs of progress on a new fiscal stimulus deal.
Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell
by Mark Vickery
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales
by Zacks Equity Research
Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.
Align's (ALGN) ClinCheck Suite Now Commercially Available
by Zacks Equity Research
Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.
Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 28.83% and 10.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM
by Zacks Equity Research
Zacks.com featured highlights include: DKS, ATVI, TMO, FBHS and TSM